Drug Combination Details

General Information of the Combination (ID: C69078)
Name Voglibose   NP Info  + Alogliptin   Drug Info 
Structure +
Disease
Type 2 diabetes mellitus [ICD-11: 5A11]
Phase 3 [1]
Prediabete [ICD-11: 5A40]
Investigative [2]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    In-vivo Model Alogliptin (0.03%) and voglibose (0.001%) alone or in combination were administered in the diet to prediabetic db/db mice.
                    Experimental
                    Result(s)		 Chronic treatment with alogliptin in combination with voglibose concurrently increased active GLP-1 circulation, increased insulin secretion, decreased glucagon secretion, prevented the onset of the disease, and preserved pancreatic beta-cells and islet structure in prediabetic db/db mice.
References
Reference 1 ClinicalTrials.gov (NCT01263509) Long-term Safety Study of Alogliptin Used in Combination With alpha-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan.
Reference 2 Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab. 2010 Mar;12(3):224-33.
 Download Picture         KEGG Link